Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17723 | 0.85 | GAA (0.52) | CYP1A2CYP2D6HSD17B10TBXAS1SMN1; SMN2 | |
| Methane SCHEMBL28846175 | 0.83 | GAA (0.51) | CYP1A2CYP2D6HSD17B10TBXAS1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15648328 | 0.83 | GAA (0.51) | CYP1A2CYP2D6HSD17B10TBXAS1SMN1; SMN2 | |
| Benzophenone SCHEMBL28209504 | 0.80 | ELANE (0.51) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL17003209 | 0.79 | HSD17B10 (0.64) | CYP1A2CYP2D6HSD17B10SMN1; SMN2GAA | |
| SCHEMBL693428 | 0.79 | HSD17B10 (0.64) | CYP1A2CYP2D6HSD17B10SMN1; SMN2GAA | |
| SCHEMBL27500000 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| Toluene SCHEMBL27616428 | 0.76 | MEN1 (0.49) | CYP1A2HSD17B10SMN1; SMN2GAAMEN1 | |
| SCHEMBL11823250 | 0.75 | ALDH1A1 (0.54) | HSD17B10TBXAS1SMN1; SMN2GAAMEN1 | |
| Phenol SCHEMBL27447861 | 0.75 | KMT2A (0.47) | HSD17B10SMN1; SMN2GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903128-B2 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040102496-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2004-05-27 | — | — | US | disclosed |
| US-6668527-B2 | Antiinflamamtory agents; autoimmune disease | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-6667331-B2 | For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )-3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-05-29 | — | — | US | disclosed |
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, CCR10 | CYP1A2 2447/4885CYP2D6 1319/4885HSD17B10 1300/4885 |
| US-20040102496-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, VSIG8 | CYP1A2 2567/4885CYP2D6 1406/4885HSD17B10 1548/4885 |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, CCR10, SELPLG | CYP1A2 2557/4885CYP2D6 1268/4885HSD17B10 949/4885 |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELP, SELPLG | CYP1A2 2322/4885CYP2D6 2018/4885HSD17B10 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.